Clinical trial
Secukinumab Safety and Efficacy in Juvenile Psoriatic Arthritis (JPsA) and…
NCT03031782 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT03031782 |
|---|---|
| Title | Secukinumab Safety and Efficacy in Juvenile Psoriatic Arthritis (JPsA) and Enthesitis-related Arthritis (ERA) |
| Official title | A Three-part Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Secukinumab Treatment in Juvenile Idiopathic Arthritis Subtypes of Psoriatic and Enthesitis-related Arthritis |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Juvenile Psoriatic Arthritis, Enthesitis-related Arthritis |
| Intervention type | Drug, Other |
| Interventions | secukinumab, placebo |
| Enrollment | 86 |
| Start date | May 23, 2017 |
| Primary completion | Oct 7, 2020 |
| Completion | Nov 9, 2020 |
| First posted | Jan 26, 2017 |
| Last update posted | Aug 15, 2022 |
| Countries | Belgium, Germany, Italy, Poland, Russia, South Africa, Spain, Turkey (Türkiye), United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: